Pantoprazole Kalceks (Pantoprazole)

Pantoprazole Kalceks is a proton pump inhibitor that acts on gastric acid secretion pathways.

• Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis.
• Peptic ulcer disease: supports ulcer healing and reduces recurrence risk.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition.

• Pantoprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By binding covalently to the pump’s sulfhydryl groups, it blocks the final step of acid production, leading to sustained reduction of gastric acidity across multiple dosing intervals.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: usually self‑limiting.
• Nausea or abdominal discomfort.
• Flatulence or bloating.
• Constipation.
• Dry mouth.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis, angioedema).
• Clostridioides difficile‑associated colitis.
• Acute interstitial nephritis.
• Low magnesium levels (hypomagnesemia) with prolonged use.
• Fracture risk with long‑term high‑dose therapy.
• Liver enzyme elevations.

Before initiating therapy, consider the following safety points:

• Assess renal and hepatic function: dose adjustment may be required in severe impairment.
• Review concomitant medications: potential for altered absorption or efficacy.
• Evaluate for Helicobacter pylori infection: eradication therapy may be needed concurrently.
• Monitor long‑term users for bone health and electrolyte disturbances.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Pantoprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Antiretroviral protease inhibitors (e.g., atazanavir, nelfinavir): reduced absorption leading to therapeutic failure.
• Certain antifungal agents (ketoconazole, itraconazole): markedly decreased bioavailability.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR, requiring more frequent monitoring.
• Methotrexate: reduced renal clearance may raise systemic exposure.
• Digoxin: modest rise in serum concentrations.
• Clopidogrel: potential reduction in antiplatelet effect.
• Iron supplements: decreased absorption; separate dosing by at least 2 hours.